

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10575193
	Filing Date		2006-10-24
	First Named Inventor	Hattori et al.	
	Art Unit	1645	
	Examiner Name	Michael Edward Szperka	
	Attorney Docket Number	14875-0160US1	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575193
Filing Date	2006-10-24
First Named Inventor	Hattori et al.
Art Unit	1645
Examiner Name	Michael Edward Szperka
Attorney Docket Number	14875-0160US1

1	SHIELDS et al., "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R," J. Biol. Chem., 276:6591-6604 (2001)	<input type="checkbox"/>
2	TARDITI et al., "Selective high-performance liquid chromatographic purification of bispecific monoclonal antibodies," J. Chromatogr., 599:13-20 (1992)	<input type="checkbox"/>
3	TEN KATE et al., "Effect of isoelectric point on biodistribution and inflammation: imaging with indium-111-labelled IgG," Eur. J. Nucl. Med., 17:305-309 (1990)	<input type="checkbox"/>
4	TSURUSHITA et al., "Design of humanized antibodies: From anti-Tac to Zenapax," Methods, 36:69-83 (2005)	<input type="checkbox"/>
5	WU et al., "Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract," J. Mol. Biol., 368:652-65 (2007)	<input type="checkbox"/>
6	YAMASAKI et al., "Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors," J. Pharmacol. Exp. Ther., 301:467-477 (2002)	<input type="checkbox"/>
7	YANG et al., "Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation," Protein Eng., 16:761-770 (2003)	<input type="checkbox"/>
8	ZUCKIER et al., "Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life," Cancer Res., 58:3905-08 (1998)	<input type="checkbox"/>
9	International Search Report for App. Ser. No. PCT/JP2009/057309, mailed July 7, 2009, 8 pages	<input type="checkbox"/>
10	EXAMINER MEERA NATARAJAN, USPTO Restriction Requirement in U.S. App. Ser. No. 12/295,039, dated October 12, 2010, 9 pages	<input type="checkbox"/>
11	International Preliminary Report on Patentability for App. Ser. No. PCT/JP2007/057036, dated October 21, 2008, 6 pages	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575193
Filing Date	2006-10-24
First Named Inventor	Hattori et al.
Art Unit	1645
Examiner Name	Michael Edward Szperka
Attorney Docket Number	14875-0160US1

12	International Search Report for App. Ser. No. PCT/JP2007/057036, dated May 1, 2007, 2 pages	<input type="checkbox"/>
13	European Search Report for App. Ser. No. 07 74 0494, dated September 3, 2009, 3 pages	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.